GSK.L - GlaxoSmithKline plc
| Previous close | 1,384.60 |
| Open | 1,384.00 |
| Bid | 1,372.00 x 0 |
| Ask | 1,450.00 x 0 |
| Day's range | 1,380.40 - 1,400.60 |
| 52-week range | 1,280.92 - 2,746.59 |
| Volume | |
| Avg. volume | 8,222,806 |
| Market cap | 57.69B |
| Beta (5Y monthly) | 0.28 |
| PE ratio (TTM) | 12.77 |
| EPS (TTM) | 1.09 |
| Earnings date | 26 Jul 2023 |
| Forward dividend & yield | 0.56 (4.08%) |
| Ex-dividend date | 18 May 2023 |
| 1y target est | N/A |
Fool.co.uk3 FTSE 100 stocks I don’t think will stay cheap for long
The FTSE 100’s lack of growth in recent years has led to some stocks looking curiously undervalued. Here are my three best bargains right now. The post 3 FTSE 100 stocks I don’t think will stay cheap for long appeared first on The Motley Fool UK.
- Reuters
India's GlaxoSmithKline Pharma's pre-tax profit falls on govt pricing caps
India's GlaxoSmithKline Pharmaceuticals Ltd reported an 8.6% fall in its pre-tax profit for the fourth quarter on Wednesday, hurt by the government's curbs on pricing of some essential medicines. Consolidated profit before tax dropped to 1.90 billion rupees ($23.23 million) for the quarter ended March 31, from 2.08 billion rupees a year earlier, the Indian unit of UK's GSK Plc said in an exchange filing. Revenue from operations at the maker of Augmentin antibiotic and T-Bact ointment fell 2.7% to 7.87 billion rupees.
Business WireBELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition
MONTREAL, May 16, 2023--BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU.TO) ("BELLUS" or the "Company") today announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding of a special meeting (the "Special Meeting") of shareholders of BELLUS ("Shareholders") on June 16, 2023. At the Special Meeting, Shareholders will be asked to consider and, if deemed advisable, to adopt a special resolution (the "Arrangement Resolution") approving the previousl
ReutersUS Supreme Court rejects Teva challenge to $235 million GSK award in patent dispute
The U.S. Supreme Court on Monday declined to hear Teva Pharmaceuticals USA Inc's challenge to a $235 million award to GlaxoSmithKline LLC in a patent dispute over generic drugs involving a heart medication. The justices turned away Israel-based Teva's appeal of a lower court's ruling reinstating the jury award for U.K.-based GSK. The case involves "skinny labels," which allow generic drugmakers to avoid patent lawsuits if a generic drug's label omits potentially infringing uses of a brand-name drug.
Fool.co.ukIf I’d invested £5k in GSK shares one year ago here’s what I’d have today
GSK shares have disappointed lately, but today's low valuation and rising yield could make now the perfect time to buy. The post If I’d invested £5k in GSK shares one year ago here’s what I’d have today appeared first on The Motley Fool UK.
Fool.co.ukI’d buy 665 GSK shares for £500 a year in passive income
GSK shares already feature in our writer's passive income portfolio. He plans to buy more to boost his annual dividend payouts. The post I’d buy 665 GSK shares for £500 a year in passive income appeared first on The Motley Fool UK.
Fool.co.uk3 FTSE 100 and FTSE 250 value stocks I’d buy right now
The London Stock Exchange is packed with top value stocks offering low earnings multiples and big dividend yields. These three are on my shopping list. The post 3 FTSE 100 and FTSE 250 value stocks I’d buy right now appeared first on The Motley Fool UK.
Simply Wall St.Interested In GSK's (LON:GSK) Upcoming UK£0.14 Dividend? You Have Four Days Left
GSK plc ( LON:GSK ) is about to trade ex-dividend in the next 4 days. The ex-dividend date is one business day before...
Yahoo Finance UKTrending tickers: GSK | THG | Beazley | Disney
The latest investor updates on stocks that are trending on Friday.
Yahoo Finance UKWall Street loses ground as FTSE 100 closes higher on UK economy growth
FTSE 100 closes the week higher as the UK economy returned to growth.
Motley FoolThe FDA Just Approved an RSV Vaccine -- and It Isn't From Moderna or Pfizer
Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) are two healthcare companies aiming to produce a vaccine for the respiratory syncytial virus (RSV). In trials, their vaccine candidates have been proving highly effective, and it may not be long before these COVID-19 vaccine makers are fighting for market share again -- this time in the RSV market. The Food and Drug Administration (FDA) recently approved an RSV vaccine, and it wasn't from either of these two companies.
- Simply Wall St.
GSK plc (LON:GSK) is favoured by institutional owners who hold 82% of the company
Key Insights Significantly high institutional ownership implies GSK's stock price is sensitive to their trading actions...
Yahoo Finance VideoGSK’s vaccine against RSV wins FDA approval
Yahoo Finance’s Anjalee Khemlani joins the Live show to discuss the FDA’s approval of GlaxoSmithKline’s (GSK) vaccine against RSV.
AFPUS becomes first country to approve RSV vaccine
The United States on Wednesday approved the world's first vaccine for the Respiratory Syncytial Virus (RSV), the culmination of a decades-long hunt to protect vulnerable people from the common illness. RSV is a common virus that normally causes mild, cold-like symptoms, but can be serious for infants and the elderly, as well as those with weak immune systems and underlying conditions.
AFPUS approves world's first RSV vaccine
The United States on Wednesday approved GSK's Arexy vaccine against Respiratory Syncytial Virus (RSV), which can cause severe pneumonia and bronchiolitis in infants and the elderly.GSK's Arexy has been recommended for approval by the European Union's drug watchdog, the European Medicines Agency, whose positive opinions are normally formally followed by the European Commission.
Business WireUS FDA Approves GSK’s AREXVY, the World’s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults
PHILADELPHIA, May 03, 2023--US FDA approves GSK’s AREXVY, the world’s first respiratory syncytial virus (RSV) vaccine for older adults
The TelegraphInvestors may be sceptical, but this unloved stock has much to offer – and a lowly valuation
Here is an unloved stock that offers a new group structure, the potential resolution of legal woes, the presence of an activist investor, a clear strategy, a building pipeline of vaccines and medicines – and all with a lowly valuation.
Yahoo FinancePfizer to shift focus to new products amid decline in COVID sales
Pfizer reported strong earnings for the first quarter of the year, despite a decrease in COVID product demand. However, investors are wary of the company's anticipated product launches this year.
Yahoo Finance VideoWhy the human genome could be health care’s holy grail
23andMe Co-founder & CEO Anne Wojcicki says we’ve only seen the tip of the iceberg for human genomics and DNA research. “Look at all the explosion of all these new technologies with gene therapy, with CRISPR (CRSP), with RNA technologies and understanding the human genome,” Wojcicki told Yahoo Finance at the Milken Global Conference in Beverly Hills, California. Wojcicki says she’s ‘disappointed’ in the lack of progress around genomics, despite having just crossed a significant milestone, 20 years since the first complete sequencing of the human genome. “I think part of the reason is that genetics tells you a lot about what you're at risk for and it doesn't necessarily financially pay to get you that preventative information and to intervene in that way versus just treating people once they have a disease.” The 23andMe (ME) CEO also says they are looking into building new partnerships with pharmaceutical giants once the company’s partnership with GlaxoSmithKline (GSK) ends in July. Interview Highlights: 1:29 How genetics can tell us more about human diversity 2:20 Why 23andMe CEO is ‘disappointed’ about genome adoption 5:00 Wojcicki on 23andMe partnership with pharma giant GSK 7:15 Genetics needs to be part of medical school training 8:26 What’s next for 23andMe
Yahoo Finance23andMe CEO: We see more opportunities in DNA partnerships
23 & Me CEO Anne Wojicki reveals the next key opportunity for her company.
Fool.co.ukIs the GSK share price going higher — or nowhere?
The GSK share price has dropped nearly 6% since its 2023 high earlier in April. With things looking up for this biopharma giant, do I buy now or wait? The post Is the GSK share price going higher — or nowhere? appeared first on The Motley Fool UK.
Fool.co.ukHere’s the GSK dividend forecast for 2023 and 2024!
The GSK share price offers solid all-round value for money right now. Should investors buy the FTSE firm based on current dividend forecasts? The post Here’s the GSK dividend forecast for 2023 and 2024! appeared first on The Motley Fool UK.
- Fool.co.uk
Is this star FTSE 100 stock set for take-off after Q1 results surprise?
GSK is a star FTSE 100 stock whose price has fallen over 15% in the past year, but its Q1 2023 revenue and profits beat estimates by a long way. The post Is this star FTSE 100 stock set for take-off after Q1 results surprise? appeared first on The Motley Fool UK.
Motley FoolWas This Acquisition a Savvy Play by This Big Pharma Stock?
Earlier this month, U.K.-based drugmaker GSK (NYSE: GSK) reached a deal to buy Canadian biotech company Bellus Health (NASDAQ: BLU) for $2 billion in cash. Should GSK's deal for Bellus Health be approved by regulatory authorities and a two-thirds majority of the latter's shareholders, the former will pick up a promising drug candidate, camlipixant, that aims to treat refractory chronic cough (RCC). Surprisingly, there are no approved therapies for RCC in the United States or the European Union.
ZacksGSK (GSK) Tops Q1 Earnings Estimates
Glaxo (GSK) delivered earnings and revenue surprises of 5.88% and 1.28%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?